All News

Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults who are candidates for systemic therapy or phototherapy.

Top news of the week from Specialty Pharmacy Times.

Phase 3 data show combination therapy demonstrates clinical benefit as first-line treatment.

A antiviral has been FDA-approved, just in time for flu season.

Amgen has announced that it will reduce the price of its cholesterol drug evolocumab (Repatha) by 60%, from its annual list price of $14,100.

Amgen will make evolocumab (Repatha) available at a list price of $5850, a 60% reduction from its annual list price of $14,1000.

Drug manufacturers, patient advocates, and professional organizations are giving a big thumbs-up to the SUPPORT for Patients and Communities Act.

Amgen will make evolocumab (Repatha) available at a list price of $5850, a 60% reduction from its annual list price of $14,100.

New analysis examines the role of the HIV/AIDS epidemic in cancer survival rates among adolescents and young adults.

Coinfection with HIV and tuberculosis may affect drug-related adverse events, hospital readmissions, and treatment duration.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Patients with rheumatoid arthritis who achieve low disease activity or remission may successfully taper their biologic disease-modifying antirheumatic drugs, saving costs as a result.

Study explores the effect of microglia dysregulation on progression of neurodegeneration in disorders such as Alzheimer disease and amyotrophic lateral sclerosis.

The approval marks the first new antiviral flu treatment with a novel mechanism of action backed by the agency in nearly 20 years.

Officials with the FDA have approved baloxavir marboxil (Xofluza, Shionogi) for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours.

Breckenridge Pharmaceutical's Clobazam Tablets, CIV, generic for Onfi® Tablets (Lundbeck), has been granted FDA approval for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older.

Mobile technology has helped to facilitate communication between pharmacists, patients, and their caregivers.

ViiV Healthcare has submitted a New Drug Application (NDA) for its single-tablet, 2-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.

Study compares 2-year survival between patients with metastatic non-small cell lung cancer treated at academic and community centers.

Certain environmental conditions, such as salinity and temperature, may incite structural changes in myelin sheaths.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Chickenpox parties coordinated through social media are becoming a dangerous trend due to the anti-vaccine movement.

Australia on track to achieve World Health Organization targets for eliminating hepatitis C virus over the next 10 to 15 years.

According to the complaint filed with the consent decree, Keystone's products were not manufactured, processed, packed or held according to CGMP requirements.

The vaccine, produced by Seqirus, was first approved in the United States in August 2016 for adults 18 and older.

To target the infrastructure supporting the illegal online sales of drugs, a series of recent OCI cybercrime investigations focused on credit card processors involved in an arrangement known as “transaction laundering” or “factoring.”

New data from the investigational multiple sclerosis (MS) drug evobrutinib showed that the therapy reduced lesions and decreased annual relapse rates in patients with relapsing MS.

A post hoc analysis of clinical trial data showed oral ozanimod improved cognitive processing speed and reduced annualized relapse rates and MRI lesions in multiple sclerosis.